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Abstract: Chronic obstructive pulmonary disease (COPD) is a debilitating disease characterized 
by inﬂ  ammation-induced airﬂ  ow limitation and parenchymal destruction. In addition to pul-
monary manifestations, patients with COPD develop systemic problems, including skeletal 
muscle and other organ-speciﬁ  c dysfunctions, nutritional abnormalities, weight loss, and 
adverse psychological responses. Patients with COPD often complain of dyspnea on exertion, 
reduced exercise capacity, and develop a progressive decline in lung function with increasing 
age. These symptoms have been attributed to increases in the work of breathing and in impair-
ments in gas exchange that result from airﬂ  ow limitation and dynamic hyperinﬂ  ation. However, 
there is mounting evidence to suggest that skeletal muscle dysfunction, independent of lung 
function, contributes signiﬁ  cantly to reduced exercise capacity and poor quality of life in these 
patients. Limb and ventilatory skeletal muscle dysfunction in COPD patients has been attributed 
to a myriad of factors, including the presence of low grade systemic inﬂ  ammatory processes, 
nutritional depletion, corticosteroid medications, chronic inactivity, age, hypoxemia, smoking, 
oxidative and nitrosative stresses, protein degradation and changes in vascular density. This 
review brieﬂ  y summarizes the contribution of these factors to overall skeletal muscle dysfunction 
in patients with COPD, with particular attention paid to the latest advances in the ﬁ  eld.
Keywords: skeletal muscles, chronic obstructive pulmonary disease, diaphragm, quadriceps, 
fatigue, disuse, atrophy, smoking, exercise
It has long been recognized that COPD is a systemic disease in which several 
extrapulmonary manifestations, including cachexia and skeletal muscle dysfunction, 
contribute to morbidity and mortality. Functionally, skeletal muscle dysfunction in 
COPD patients is characterized by signiﬁ  cant reduction in muscle strength and endur-
ance. It is structurally characterized by loss of muscle mass and cross-sectional area 
(muscle atrophy), ﬁ  ber type distribution (reduction in the proportion of oxidative ﬁ  bers 
and increases in the proportion of glycolytic ﬁ  bers), oxidative metabolic capacity 
(attenuation of mitochondrial enzyme activities and expression) and capillary distribu-
tion (signiﬁ  cant loss of capillary density). Although disuse and inactivity are important 
contributors to the pathogenesis of skeletal muscle dysfunction in COPD patients, several 
other systemic and local factors are also involved. These include systemic inﬂ  ammation, 
malnutrition, corticosteroid usage, hypoxemia, aging, smoking and local factors such 
as the production of reactive oxygen (ROS) and nitrogen species (RNS) and enhanced 
protein degradation inside muscle ﬁ  bers, a result of increased activities of the protea-
somal and lysosomal pathways and activation of calpains and caspases.
Evidence of skeletal muscle dysfunction 
in patients with COPD
It has been well established that skeletal muscle function (strength and endurance) and 
structure (ﬁ  ber size, ﬁ  ber type distribution, capillary density and metabolic capacity) International Journal of COPD 2008:3(4) 638
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are altered in patients with COPD. Speciﬁ  c abnormalities 
of these muscles include depressed muscle strength, reduc-
tion in muscle endurance, muscle ﬁ  ber atrophy, and ﬁ  ber 
type shift.
Depressed muscle strength
Alterations in muscle strength (deﬁ  ned as the capacity of 
the muscle to generate force) in COPD patients primarily 
involves the lower limb muscles, with quadriceps femoris 
muscle strength being 20% to 30% lower in patients with 
moderate to severe COPD as compared to control subjects 
(Gosselink et al 1996; Bernard et al 1998; Franssen et al 
2005). The degree of reduced limb muscle strength corre-
lates with the severity of the disease process (Bernard et al 
1998) (Figure 1). In addition, it has been well established 
that reduced limb muscle strength in patients with moderate 
COPD contributes to poor exercise performance, increased 
dyspnea and worsening of quality of life (Gosselink et al 
1996; Mostert et al 2000). Furthermore, relatively low limb 
muscle strength is a powerful predictor of mortality in severe 
COPD patients (Swallow et al 2007b).
Reduction in muscle endurance
Many reports have conﬁ  rmed that the endurance (deﬁ  ned as 
the capacity of the muscle to maintain a certain force over 
time) of limb muscles is attenuated by about 30% in patients 
with moderate COPD and that poor muscle endurance in 
these patients correlates positively with physical activity 
index, forced expiratory volume in one second (FEV1) and 
resting partial pressure of oxygen in arterial blood (PaO2) 
(Serres et al 1998; Van’t et al 2004). Allaire and colleagues 
(2004) have concluded that attenuation of quadriceps muscle 
endurance in COPD patients is related to reduced oxidative 
capacity of the mitochondria and to the development of 
oxidative stress in the muscle. Recently, this reduction of 
muscle endurance time has been conﬁ  rmed using artiﬁ  cial 
stimulation protocols (Figure 2) (Swallow et al 2007a).
Muscle ﬁ  ber atrophy
It has been well established that limb muscles of COPD 
patients develop signiﬁ  cant reductions in mass and cross-
sectional areas (Engelen et al 2000c; Hopkinson et al 2007). 
The magnitude of loss of thigh muscle mass is relatively 
greater than that of whole body weight, indicating a pref-
erential loss of muscle tissue over other body tissues in 
emaciated COPD patients (Bernard et al 1998). The degree 
to which ﬁ  ber atrophy contributes to reduced limb muscle 
strength in these patients remains debatable. On one hand, 
several reports have described that when limb muscle strength 
is normalized per cross-sectional area or mass, no differ-
ences can be observed between COPD patients and control 
subjects (Bernard et al 1998; Engelen et al 2000a, 2000c). 
This conclusion is supported by the observation that in vitro 
maximum tetanic tension of vastus lateralis muscles, normal-
ized per muscle bundle cross-sectional area, is similar in 
COPD patients and control subjects (Debigare et al 2003a). 
These studies clearly lend credence to the notion that muscle 
atrophy is the sole cause of reduced limb muscle strength and 
endurance in COPD patients. On the other hand, Malaguti 
and colleagues (2006) have used standard ratio, power func-
tion ratio and analysis of covariance to normalize isokinetic 
dynamometry parameters (peak torque, isometric strength 
and total work) of leg muscles to leg muscle mass and have 
shown that greater muscle mass is needed to generate a 
given functional output in COPD patients as compared with 
control subjects. As such, they suggest that factors other 
than atrophy might play a role in explaining skeletal muscle 
dysfunction in COPD patients (Malaguti et al 2006). Their 
position is supported by several reports that have documented 
the presence of intrinsic abnormalities inside limb muscle 
ﬁ  bers of COPD patients, especially in the form of contractile 
fatigue (Mador et al 2000, 2001, 2003a, 2003b; Saey et al 
2003, 2005, 2006). A good example of these reports is that 
of Mador and colleagues (Jeffery et al 2000) who found a 
signiﬁ  cant decrease in quadriceps twitch force of patients 
with severe COPD – by more than 20% within 30min of 
termination of exercise – a value that was signiﬁ  cantly greater 
than that observed in control subjects. Furthermore, Mador 
and colleagues (2003a) have also compared the degree of 
fatigability in limb muscles of COPD patients and control 
subjects exercising at work loads designed to generate 
similar absolute oxygen consumption and have described 
signiﬁ  cantly greater falls in quadriceps muscle twitch force 
in COPD patients than in control subjects, suggesting that 
limb muscles of COPD patients are more fatigable than those 
of healthy individuals.
Fiber type shift
In severe COPD patients, quadriceps muscles undergo sig-
niﬁ  cant redistribution of ﬁ  ber type ratios, manifested as a 
reduction in the proportion of type I (slow-twitch oxidative) 
ﬁ  bers and augmentation of the proportion of type IIb (fast 
twitch glycolytic) ﬁ  bers. An early report by Whittom and 
colleagues (1998) demonstrated that type I ﬁ  ber proportion 
declines by 20%, whereas the proportion of type IIb ﬁ  bers 
increases by 10% in patients with severe COPD. A subsequent International Journal of COPD 2008:3(4) 639
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Figure 1 A) Group mean values (±SD) for strength of quadriceps, pectoralis major and latissimus dorsi muscles obtained from normal subjects and COPD patients. Note 
signiﬁ  cant reduction in strength in each of three muscle groups in patients with COPD, as compared to normal subjects. *P  0.05. B)  Relationship between FEV1 (percentage 
of predicted) and quadriceps muscle strength showing signiﬁ  cant positive relationship (r = 0.55, p  0.0005) Copyright © 1998.   Adapted from Bernard S, LeBlanc P,   Whittom F, 
et al 1998. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 158:629–34.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second.International Journal of COPD 2008:3(4) 640
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study by Maltais and colleagues (1999) conﬁ  rmed a shift 
toward type II ﬁ  bers and a reduction in the proportion of type I 
ﬁ  bers in the vastus lateralis muscles of patients with severe 
COPD. Recent meta-analysis has revealed that the proportion 
of type I ﬁ  bers in the vastus lateralis muscle correlates with 
FEV1, FEV1/forced vital capacity (FVC) and the body mass 
index (BMI) in patients with moderate to severe COPD (Gosker 
et al 2007b). Although the exact functional consequences 
of this ﬁ  ber type redistribution remain under investigation, 
the fact that type II ﬁ  bers are fatigue-prone suggests that an 
increased proportion of type II ﬁ  bers might be an important 
factor in increased leg muscle fatigability and reduced endur-
ance. It should be emphasized that ﬁ  ber type shifting towards 
more glycolytic ﬁ  bers in limb muscles of COPD patients is 
associated with reductions in muscle oxidative capacity, as 
shown by signiﬁ  cantly lower levels of cytochrome c oxidase 
and succinate dehydrogenase in the quadriceps of patients 
with severe COPD (Gosker et al 2002). In a subsequent study, 
Gosker and colleagues (2007a) have reported that reduced 
oxidative capacity of the quadriceps of COPD patients can 
be attributed, in part, to reduction in mitochondrial density in 
that muscle. The exact mechanisms responsible for reduced 
mitochondrial density in limb muscles of COPD patients are 
as yet unclear, however recent observations of Remels and 
colleagues (2007), that peroxisome proliferator-activated 
receptors (PPARs), PPAR-γ co-activator PGC-1α and the 
mitochondrial transcription factor A (TFAM) are signiﬁ  cantly 
lower in quadriceps of cachectic patients with severe COPD, 
suggest that mitochondrial biogenesis is signiﬁ  cantly reduced 
in limb muscles of these patients.
Consequences of skeletal muscle 
dysfunction in patients with COPD
Reduced exercise capacity and dyspnea on exertion are the 
most common complaints in patients with COPD. These 
symptoms cannot be explained entirely on the basis of a 
decline in lung function and impaired gas exchange. Indeed, 
Killian and colleagues (1992) measured leg effort and dys-
pnea in 97 patients with chronic airway obstruction during 
maximal cycle ergometry and concluded that the intensity 
of leg effort is more crucial than the degree of dyspnea. In 
addition, observations that considerable exercise limitation 
persists in COPD patients who have undergone lung trans-
plantation, despite marked improvement in lung function, and 
in COPD patients that have experienced an improvement in 
airway obstruction by using bronchodilators, provides evi-
dence in favor of a poor relationship between lung function 
and exercise performance (Lands et al 1999; Saey et al 2003). 
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Figure 2 Force decline of quadriceps femoris muscle during repetitive magnetic stimulation of femoral nerve in control subjects and COPD patients. The curves were 
signiﬁ  cantly different at 10, 20, 30, and 40 trains Copyright © 2007.  Adapted from Swallow EB, Gosker HR,   Ward KA, et al 2007a. A novel technique for nonvolitional assessment 
of quadriceps muscle endurance in humans. J Appl Physiol, 103:739–46.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(4) 641
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Reduced exercise capacity and limb muscle weakness lead to 
COPD patient disability and correlate with higher utilization 
of health care resources. This conclusion is supported by 
Decramer and colleagues (1997) in their analysis of factors 
associated with higher utilization of health care resources 
in 57 stable severe COPD patients. They have shown that 
quadriceps muscle force alone, rather than pulmonary func-
tion and exercise capacity, is a signiﬁ  cant determinant of 
higher utilization of health care resources. Montes de Oca 
and colleagues (2006) have reached a similar conclusion. 
Skeletal muscle dysfunction also contributes to poor clinical 
outcomes, as indicated by a signiﬁ  cant relationship between 
mid-thigh cross-sectional area and mortality in stable COPD 
patients (Marquis et al 2002).
Ventilatory muscle function
There is increasing evidence that the degree of skeletal 
muscle dysfunction in COPD patients is not homogenous 
between various muscle groups. Indeed, Gosselink and col-
leagues (2000) have found that inspiratory muscle strength is 
more severely reduced than that of expiratory muscle strength 
and that proximal upper muscle strength is more impaired 
than distal upper limb strength in patients with moderate 
COPD. Similarly, Franssen and colleagues (2005) have 
described a relatively milder reduction in arm strength than 
that of leg strength, which is more severely attenuated. The 
reasons behind these differences between various skeletal 
muscles remain unclear, however many investigators have 
proposed that daily muscle recruitment and activation largely 
determines the degree to which a given muscle is affected in 
these patients. For instance, the ventilatory muscles, particu-
larly the diaphragm, have different workloads than do the 
lower limb muscles. Ventilatory muscles are in a chronically 
overloaded state due to increased work of breathing brought 
on by airﬂ  ow obstruction and hyperinﬂ  ation.
In contrast, limb muscles, especially lower extremity 
muscles, are in a chronically underloaded state due to chronic 
inactivity and disuse. These dissimilar loading patterns are 
the likely cause of biochemical and structural adaptations that 
develop in the ventilatory muscles but that are not present 
in lower limb muscles of COPD patients. For instance, the 
diaphragms of patients with severe COPD have increased 
proportions of type I ﬁ  bers as compared with control sub-
jects. This was documented for the ﬁ  rst time by Levine and 
colleagues (1997) who reported that the proportion of type 
I ﬁ  bers averages 64% of total ﬁ  bers in the diaphragms of 
patients with severe COPD whereas the proportion of these 
ﬁ  bers averages only 45% of total ﬁ  ber number in control 
diaphragms. It should be emphasized that this rise in the 
proportion of type I ﬁ  bers in the diaphragm is evident only 
in severe, as opposed to moderate, COPD patients (Orozco-
Levi et al 1999; Orozco-Levi 2003).
Levine and colleagues (2003) have also demonstrated 
that a negative exponential relationship exists between the 
proportion of type I ﬁ  bers in the diaphragm and resting FEV1 
(% predicted), implying that a reduction in FEV1 down to 
60% predicted value has no inﬂ  uence on the proportion of 
type I ﬁ  bers, and that a further decline in FEV1 is accompa-
nied by a signiﬁ  cant increase in the proportion of these ﬁ  bers. 
These results suggest that diaphragm ﬁ  ber type switching, 
to more fatigue resistant ﬁ  bers, is highly dependent on the 
severity of the pulmonary disease process in COPD patients. 
Moreover, ﬁ  ber type switching toward an increase in pro-
portion of type I ﬁ  bers is not limited to the diaphragm but 
can also be observed in other inspiratory muscles. Indeed, 
Levine and colleagues (2006) have reported an increase in 
the proportion of type I ﬁ  bers, from an average of 51% in 
the parasternal intercostals of control subjects to 73% in the 
same muscles of patients with severe COPD.
Other adaptive changes that have been observed in the 
diaphragm of COPD patients include increased mitochondrial 
density, increased oxidative capacity and enhanced myosin 
ATPase activity (Orozco-Levi et al 1999; Levine et al 2002). 
Additionally, relatively shorter sarcomere lengths have 
been measured in the diaphragms of COPD patients with 
hyperinﬂ  ation, as compared to those without hyperinﬂ  ation 
(Levine et al 1997; Orozco-Levi et al 1999). This shortening 
of diaphragm sarcomeres represents an adaptive response 
designed to reverse the negative inﬂ  uence of hyperinﬂ  a-
tion on the force-length characteristics of the diaphragm 
that helps to preserve diaphragm ﬁ  ber capacity to generate 
tension. It should be emphasized that despite several com-
pensatory adaptations in the diaphragm of COPD patients, 
maximal strength of this muscle, as measured by maximal 
transdiaphragmatic pressure (Pdimax), remains about 30 to 
40% lower in COPD patients as compared with control 
subjects (Bellemare and Grassino 1983; Polkey et al 1996). 
Gosselink and colleagues (2000) have also reported that 
inspiratory muscle strength in patients with severe COPD, as 
measured by maximal inspiratory pressure, averaged 59% of 
that measured in control subjects.
Reduction of diaphragm strength in COPD patients 
has been traditionally attributed to hyperinﬂ  ation-induced 
shortening of diaphragmatic length, which has a negative 
inﬂ  uence on the pressure-length relationship. This view is 
supported by the observation that lung volume reduction International Journal of COPD 2008:3(4) 642
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surgery results in an increase in diaphragm length and 
restoration of Pdimax in COPD patients (Lando et al 1999). 
Moreover, intrinsic abnormalities within diaphragm muscle 
ﬁ  bers cannot be ruled out as signiﬁ  cant contributors to the 
reduced strength of this muscle in COPD patients. Indeed, 
Levine and colleagues (2003) measured maximal isometric 
force of single muscle ﬁ  bers obtained from the diaphragm 
of two severe COPD patients and reported that maximal 
force of type I and IIa ﬁ  ber was signiﬁ  cantly lower in 
these patients than in control subjects. Reduction in force 
generation of isolated diaphragm muscle ﬁ  bers has also 
been documented in patients with mild to moderate COPD 
(Ottenheijm et al 2005). This observation cannot simply 
be attributed to muscle ﬁ  ber atrophy and the reduction of 
levels of myoﬁ  lament proteins since signiﬁ  cant reduction 
in Ca++ sensitivity of skinned muscle ﬁ  bers and impaired 
cross-bridge cycling kinetics can also be observed in the 
diaphragms of COPD patients (Ottenheijm et al 2005; 
Stubbings et al 2008).
Other intrinsic abnormalities in the diaphragm of COPD 
patients include reduced passive-tension generation of 
diaphragm single ﬁ  bers. This condition can be attributed, 
in part, to selective alternative splicing of the titin gene, 
resulting in increased length of the elastic segment of the 
protein that is rich in proline, glutamate, valine, and lysine 
(Ottenheijm et al 2006a). In addition, the diaphragms of 
COPD patients manifest increased susceptibility to sar-
comere injuries, both at the basal level and in response to 
increased activation of the muscle during resistive loading 
(Orozco-Levi et al 2001).
COPD also induces upper limb muscles to develop 
adaptive changes that are different from those detected 
in lower limb muscles. For instance, Gea and colleagues 
(2001) compared exercise performance, handgrip strength 
and metabolic proﬁ  le of the deltoid muscles and found that 
handgrip strength changes very little in COPD patients, 
despite a marked reduction in exercise capacity. In addition, 
while deltoid muscle creatine kinase and phosphofructo-
kinase activities do not differ among COPD patients and 
control groups, the activities of citrate synthase and lactate 
dehydrogenase are signiﬁ  cantly greater in COPD patients, 
suggesting the presence of metabolic adapative changes in 
both mitochondrial oxidative capacity and glycolysis path-
ways (Gea et al 2001; Hernandez et al 2003).
Mechanisms of skeletal muscle 
dysfunction in COPD patients
Potential mechanisms of skeletal muscle dysfunction in 
COPD patients are summarized in Figure 3. Skeletal muscle 
dysfunction in COPD patients can be attributed to a set of 
complex interactions between many factors, both systemic 
and local.
Systemic factors
It has long been recognized that systemic factors such as 
inﬂ  ammation, malnutrition, medication, inactivity, age, 
Aging Malnutrition Chronic inactivity Smoking
Oxidative Stress
Muscle Protein Synthesis,
UPP
COPD
Apoptosis
Corticosteroids
Loss of muscle mass & fiber type shift
Protein Degradation
SKELETAL MUSCLE DYSFUNCTION
Hypoxemia
Anaboblic Hormones
Systemic Inflammation
Figure 3 Proposed mechanisms of skeletal muscle dysfunction in COPD patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; UPP, ubiquitin/proteasomal pathway.International Journal of COPD 2008:3(4) 643
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hypoxemia, and smoking exert strong effects on skeletal 
muscle performance in COPD patients.
Inﬂ  ammation
Systemic and/or local inﬂ  ammation has been identiﬁ  ed as a 
common feature of COPD. In stable COPD patients, elevated 
serum levels of C-reactive protein, ﬁ  brinogen, circulating 
leukocytes and pro-inﬂ  ammatory cytokines, including tumor 
necrosis factor-alpha (TNFα), interleukin-8 (IL8), IL6, 
soluble TNF receptors 55 (sTNF-R55) and 72 (sTNF-R75) 
have been observed (Schols et al 1996; Dentener et al 
2001; Gan et al 2004). Recently, signiﬁ  cant elevations in 
serum IL18 have been observed in patients with moderate 
to severe COPD (Petersen et al 2007b). The cellular origins 
of pro-inﬂ  ammatory cytokines in the serum of stable COPD 
patients remain unclear. One likely source is the lungs, where 
intense inﬂ  ammatory processes develop in the vasculature, 
parenchyma and airways. However, no direct correlations 
have been found between sputum and plasma concentrations 
of IL8, sTNF-R55 and sTNF-R75 in patients with mild to 
moderate COPD (Vernooy et al 2002), suggesting that organs 
other than the lungs contribute to elevated levels of systemic 
inﬂ  ammatory mediators. One such organ is skeletal muscle, 
particularly the diaphragm and intercostal muscles, where 
the work of breathing in COPD patients is elevated. This 
view is based on the observations that strenuous resistive 
breathing and whole body exercise in healthy humans, such 
as treadmill running, induce signiﬁ  cant elevations of plasma 
pro-inﬂ  ammatory cytokine levels, including IL6, IL-1β, 
and TNFα and that this production is mediated in part by 
increased oxygen radical production (Vassilakopoulos et al 
1999, 2002; Ostrowski et al 1998). This role of ventilatory 
muscles as a source of systemic inﬂ  ammation has been con-
ﬁ  rmed in an animal model of inspiratory resistive loading, 
where increased work of breathing signiﬁ  cantly upregulates 
IL6, IL1β and TNFα expressions within the diaphragm 
(Vassilakopoulos et al 2004). A recent study by Casadevall 
and colleagues (2007) has conﬁ  rmed that TNFα and IL6 
levels are signiﬁ  cantly elevated in the intercostal muscles 
of COPD patients.
The involvement of inﬂ  ammatory mediators in skeletal 
muscle dysfunction is also suggested by the observation that 
systemic inﬂ  ammation markers correlate with poor muscle 
contractile performance in COPD patients. For example, 
quadriceps muscle strength correlates negatively with serum 
IL8 levels in COPD patients during exacerbation and with 
serum IL6 and TNFα in aged COPD patients (Spruit et al 
2003; Yende et al 2006). Other authors have revealed that 
low FEV1 values correlate with increased plasma levels of 
C-reactive protein and IL6 in severe to very severe COPD 
cases and that elevated C-reactive protein levels associate 
not only with diminished limb muscle strength but also 
with reduced exercise endurance and poor health status and 
quality of life, independent of other factors such as age, sex, 
and smoking history (Broekhuizen et al 2006; Pinto-Plata 
et al 2006).
The notion that systemic inﬂ  ammation contributes to 
skeletal muscle dysfunction in COPD patients is also sup-
ported by the fact that many pro-inﬂ  ammatory cytokines can 
adversely inﬂ  uence skeletal muscle growth and contractile 
performance. This is particularly true with TNFα, which 
promotes muscle wasting by enhancing the activity of the 
ubiquitin proteasome pathway (Langen et al 2006). TNFα 
also promotes muscle wasting by inducing apoptosis (Carbo 
et al 2002). Loss of nuclei, a result of increased apoptosis in 
skeletal muscle ﬁ  bers, alters myonuclear domain size (the 
amount of cytoplasm per myonucleus), eventually result-
ing in muscle atrophy. The involvement of apoptosis in 
limb muscle wasting in COPD patients was ﬁ  rst proposed 
by Agusti and colleagues (2002), who described increased 
numbers of apoptotic nuclei in quadriceps muscles of these 
patients. TNFα might also reduce skeletal muscle oxidative 
capacity by inhibiting mitochondrial biogenesis (Valerio 
et al 2006). Finally, TNFα exerts acute inhibitory effects 
on muscle contractility (Wilcox et al 1996), which has been 
attributed to depressed sensitivity of myoﬁ  lament proteins 
to Ca++ and to enhanced generation of ROS and RNS (Reid 
et al 2002).
It should be emphasized that despite convincing docu-
mentation of elevated circulating levels of pro-inﬂ  ammatory 
cytokines in stable COPD patients, as well as in those suffer-
ing from acute exacerbations, general agreement is lacking 
about the degree to which pro-inﬂ  ammatory mediators are 
upregulated in limb muscles. On one hand, Barreiro and 
colleagues (2008b) measured various pro-inﬂ  ammatory 
cytokines in quadriceps muscles of 19 patients with severe 
COPD and substantial muscle atrophy and reported that IL6, 
IL1β, interferon-γ and TGF-β levels were not signiﬁ  cantly 
different from those detected in control subjects. TNFα 
expression was actually lower in quadriceps muscles of 
COPD patients as compared with control subjects (Barreiro 
et al 2008b). Similarly, Crul and colleagues (2007) failed 
to detect signiﬁ  cant elevations of IL8, IL6 and TNFα in 
quadriceps muscles of hospitalized and clinically stable 
COPD patients, as compared with age-matched control 
subjects.International Journal of COPD 2008:3(4) 644
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On the other hand, Montes de Oca and colleagues (2005) 
have described a more than ﬁ  vefold increase in TNFα levels 
in quadriceps of patients with severe COPD, as compared 
with control subjects. A signiﬁ  cant increase in NFκB 
nuclear binding activity (a major regulator of cytokine 
production) has also been observed in limb muscles of 
patients with severe COPD (Agusti et al 2004). More 
recently, Petersen and colleagues (2007b) have described 
signiﬁ  cant upregulation of IL18 in quadriceps muscle 
samples obtained from patients with moderate to severe 
COPD. The reasons behind these contradictory results are 
as yet unclear, but factors such as the use of relatively low 
numbers of patients, the presence or absence of hypoxemia, 
severe weight loss, exacerbation of pulmonary manifesta-
tions and the development of oxidative stress inside muscle 
ﬁ  bers might be involved.
Malnutrition
The importance of nutritional status on exercise performance 
and skeletal muscle dysfunction in COPD patients stems 
from the fact that over 30% of COPD patients undergoing 
pulmonary rehabilitation experience nutritional deple-
tion (less than 90% of ideal body weight) (Schols et al 
1993). Malnutrition in COPD patients is the result of an 
imbalance between energy intake and energy expenditure. 
Reduced dietary intake in these patients has been attributed 
to symptoms such as postprandial dyspnea, early satiety, 
fatigue and loss of appetite. Elevated energy expenditure 
has been attributed to increased work of breathing, ther-
mogenic effects of bronchodilators and systemic inﬂ  am-
mation (Baarends et al 1997; Vermeeren et al 1997). The 
reduction in body mass index in COPD patients signiﬁ  cantly 
correlates with high mortality (Landbo et al 1999). A clear 
inﬂ  uence of nutritional status on skeletal muscle contractile 
performance and structure has been documented in patients 
with anorexia nervosa (body mass index of less than 14) 
where maximum quadriceps muscle strength is signiﬁ  cantly 
reduced and marked atrophy of type I and II muscle ﬁ  bers 
is detectable (McLoughlin et al 1998). These patients also 
develop substantial reduction in limb muscle oxidative and 
glycolytic enzyme activities.
The respiratory muscles are not immune from the effects 
of malnutrition, as evidenced by a reduction in inspira-
tory and expiratory airway pressures in cachectic COPD 
patients (80% of ideal body weight), as compared with 
normal weight COPD patients (Nishimura et al 1995). It 
should be emphasized that while nutritional depletion may 
play an important role in muscle dysfunction in COPD 
patients, nutritional supplementation evokes only modest 
improvements in muscle function, suggesting that nutritional 
depletion may not be the primary mechanism responsible for 
skeletal muscle dysfunction in COPD (Ferreira et al 2000).
Medication
Among the many drugs used to treat COPD, corticosteroids 
alone are capable of eliciting skeletal muscle dysfunction 
(steroid-induced myopathy). Short periods of high-dose 
corticosteroid therapy and prolonged therapy with low-dose 
corticosteroids are commonly prescribed for acute exacer-
bations of COPD and for controlling chronic symptoms in 
some patients. Long-term therapy with relatively high doses 
of corticosteroids elicits signiﬁ  cant reduction in strength 
and atrophy of both ventilatory and limb muscles of COPD 
patients (Decramer and Stas 1992). Decramer and Stas (1992) 
also reported, in a study involving two patients with asthma 
and one with COPD, that prolonged administration of rela-
tively high doses of corticosteroids elicits very severe reduc-
tions in quadriceps muscle strength and maximum inspiratory 
and expiratory pressures. Tapering of corticosteroid therapy 
improves quadriceps muscle force and inspiratory and expira-
tory muscle strengths.
In a subsequent study, Decramer and colleagues (1994, 
1996) described severe quadriceps muscle weakness, out 
of proportion to the loss of body muscle mass, in COPD 
patients taking an average daily dose of steroids (4 mg 
of methylprednisolone) as a short-burst therapy during 
acute exacerbations. Depressed muscle contractility is 
associated with histological evidence of ﬁ  ber atrophy and 
necrosis (Decramer et al 1996). The deleterious effects 
of corticosteroids on skeletal muscle function have been 
attributed to inhibition of signaling pathways involved in 
protein synthesis, as well as to augmented protein degra-
dation, which itself is a result of increased expression and 
activity of the ubiquitin-proteasome pathway, including 
upregulation of pathway regulators known as Forkhead 
transcription factors. It should be noted that these stud-
ies on the inﬂ  uence of corticosteroid therapy on muscle 
function were conducted on COPD patients during acute 
exacerbations. To distinguish the effects of corticosteroids 
from other factors that may inﬂ  uence skeletal muscle 
function during acute exacerbations, Hopkinson and 
colleagues (2004) reported that a 2-week course of pred-
nisolone (30 mg) therapy in stable COPD patients did not 
affect quadriceps muscle strength or metabolic parameters 
during exercise, suggesting that, in the absence of acute 
exacerbation (eg, systemic inﬂ  ammation or immobility), International Journal of COPD 2008:3(4) 645
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short-term corticosteroid treatment does not in and of itself 
cause skeletal muscle weakness.
Inactivity
The fact that a great proportion of COPD patients live a 
sedentary lifestyle (no regular activity over a two year 
period) has led many investigators to attribute skeletal muscle 
dysfunction in these patients to physical deconditioning. 
Physical inactivity induces several adaptive changes in 
skeletal muscles, including reduced proportions of type I 
ﬁ  bers, attenuation of oxidative enzyme capacity, regulators 
of mitochondrial biogenesis (PPARs and PGC-1α), ﬁ  ber 
atrophy, reduction of antioxidant enzyme levels and lower 
capillary density (Franssen et al 2002; Lawler et al 2003; 
Remels et al 2007). These changes, collectively known as 
musculoskeletal deconditioning, result in signiﬁ  cant reduc-
tions in skeletal muscle strength and endurance. The degree 
of musculoskeletal deconditioning is highly dependent on the 
causes and duration of inactivity, as well as on morphologi-
cal and biochemical properties of skeletal muscles. While 
there are similar morphological, structural and biochemical 
abnormalities in the skeletal muscles of COPD patients and 
in those elicited by chronic inactivity, there is some evidence 
that physical inactivity alone does not sufﬁ  ciently explain 
the skeletal muscle dysfunction seen in COPD patients. For 
instance, one study, in which proper control subjects had 
similar physical activity levels to those of COPD patients, 
revealed reductions of quadriceps muscle endurance in the 
COPD patients that cannot be explained by a mere lack 
of physical activity since reductions in the proportion of 
type I ﬁ  bers in quadriceps muscles of COPD patients are 
relatively greater than in the control group (Couillard et al 
2002). Indeed, while sedentary lifestyle is associated with 
reduction of quadriceps muscle type I ﬁ  ber proportion, 
from 60%–65% in healthy active control subjects to about 
40% in inactive subjects (Proctor et al 1995; Houmard et al 
1998), the proportion of type I ﬁ  bers in quadriceps muscles 
of COPD patients reaches as low as 19% (Gosker et al 2002; 
Allaire et al 2004; Richardson et al 2004). It is also worth 
noting that prolonged periods of exercise training exerts a 
relatively small inﬂ  uence on the proportion of type I ﬁ  bers 
in quadriceps muscles of COPD patients, and only partially 
reverses reductions in oxidative enzyme activities (citrate 
synthase and 3-hydroxyacyl-CoA dehydrogenase) in the 
muscle (Maltais et al 1996; Whittom et al 1998).
Variant results have been published, however, regarding 
the precise relationship between physical activity and limb 
muscle endurance in COPD patients. While Serres and 
colleagues (1998) have described a positive correlation 
between quadriceps muscle endurance and physical inactivity, 
both Coronell and colleagues (2004) and Gosker and 
colleagues (2003a) have failed to ﬁ  nd a relationship between 
these parameters. These contradictory results, therefore, 
suggest that physical inactivity may contribute to, but does not 
fully explain, limb muscle dysfunction in COPD patients.
Age
COPD usually develops with advanced age. Accordingly, the 
selective effects of aging should be taken into consideration 
when analyzing the various factors responsible for muscle 
dysfunction in these patients. It has been well established that 
limb muscles of older individuals are signiﬁ  cantly smaller 
and have signiﬁ  cantly more fat and connective tissues than 
those of younger individuals (Lexell 1995). In addition, limb 
muscle strength, particularly that of the quadriceps muscle, 
has been reported to be about 39% lower in men in their 
seventies as compared to men in their twenties (Young et al 
1985). Furthermore, declines in muscle strength with aging 
correlate with the degree of atrophy of type II ﬁ  bers and are 
not limited to limb muscles. Indeed, maximum transdiaphrag-
matic pressure (Pdimax) measured at various lung volumes is 
reportedly to be approximately 25% lower in elderly subjects 
as compared to that measured in young subjects (Tolep et al 
1995). Similarly, 13% and 23% reductions in sniff Pdi and 
twitch Pdi (generated by phrenic stimulation) have been 
observed in elderly subjects, as compared to young subjects 
(Polkey et al 1997). These studies clearly indicate that aging 
contributes to poor skeletal muscle contractile performance 
in COPD patients.
Hypoxemia
Many COPD patients develop chronic moderate hypoxemia 
or may present with repeated episodes of hypoxemia. It has 
been well established that prolonged exposure to hypobaric 
hypoxia is associated with signiﬁ  cant reductions in skeletal 
muscle strength and endurance, increases in muscle atrophy 
and attenuation of mitochondrial Krebs cycle enzyme activity 
(Hoppeler et al 1990; Caquelard et al 2000). Although 
there is no direct proof of the involvement of hypoxemia in 
reduced skeletal muscle strength and endurance in COPD 
patients, there is circumstantial evidence that suggests that 
hypoxemia may contribute to the deterioration of skeletal 
muscle performance. For instance, the proportions of type I 
ﬁ  bers in quadriceps muscles are signiﬁ  cantly lower in hypox-
emic COPD patients as compared to nonhypoxemic COPD 
patients (Gosker et al 2002).International Journal of COPD 2008:3(4) 646
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Moreover, exercise endurance in COPD patients 
correlates positively with PaO2 (Serres et al 1998). Jakobsson 
and colleagues (1990) have reported that adenosine tri-
phosphate (ATP), glycogen and creatine phosphate levels 
in quadriceps muscle ﬁ  bers are signiﬁ  cantly reduced in 
COPD patients with chronic respiratory failure as compared 
to those without respiratory failure and they described a 
significant correlation between muscle metabolites and 
arterial PO2. Moreover, chronic hypoxemic COPD patients 
show greater levels of exercise-induced lipid peroxidation 
and oxidized proteins in their quadriceps muscles than do 
nonhypoxemic COPD patients (Koechlin et al 2005). As with 
the case of lower limb muscles, maximum diaphragm force 
and diaphragm endurance are both signiﬁ  cantly reduced in 
COPD patients with chronic hypoxemia, although inhalation 
of O2 for 15min elicits an increase in diaphragm strength and 
endurance (Zattara-Hartmann et al 1995).
Hypoxemia can elicit skeletal muscle dysfunctions 
through direct and indirect actions on contractile processes. 
The acute and direct inhibitory effects of hypoxia on skeletal 
muscle contractile performance have been demonstrated in 
several in vitro experiments utilizing rat diaphragm strips 
(Shee and Cameron 1990). While these experiments might 
explain the decline in limb muscle and diaphragm strength 
in severe COPD patients, the mechanisms responsible for the 
relationship between hypoxemia and ﬁ  ber type redistribution 
and alterations in the metabolic proﬁ  les of skeletal muscles 
remain unclear. Indirect inhibitory effects of hypoxemia on 
skeletal muscle function are mediated mainly through the 
release of pro-inﬂ  ammatory cytokines such as TNFα and 
IL1β (Ghezzi et al 1991). This notion is supported by the 
observations that circulating levels of TNFα and soluble 
TNFα receptors in COPD patients are signiﬁ  cantly higher 
than in control subjects and that these levels are inversely 
related to PaO2 (Takabatake et al 2000).
Smoking
Most COPD patients are current or previous smokers, 
making smoking the main risk factor for COPD. However, 
the potential effects of smoking on skeletal muscle function 
remain unclear. A recent study by Montes de Oca and col-
leagues (2008) suggests that smoking per se, independent 
of the presence of COPD, elicits skeletal muscle atrophy, as 
indicated by a reduction in the cross-sectional areas of both 
type I and II ﬁ  bers, a reduction in the expression of constitu-
tive nitric oxide synthases and augmentation of the number 
of low oxidative and highly glycolytic muscle ﬁ  bers. The 
deleterious effects of smoking on muscle metabolism have 
been further analyzed by Petersen and colleagues (2007a), 
who have reported that heavy smoking (20 cigarettes/day 
for 20 years) elicits no change in whole body protein 
breakdown but signiﬁ  cantly attenuates quadriceps muscle 
protein synthesis and augments the expression of both myo-
statin (inhibitor of muscle growth) and atrogin-1 (E3 ligase). 
These results suggest that smoking induces skeletal muscle 
ﬁ  ber atrophy as a result of inhibition of protein synthesis, 
rather than as a result of increased protein degradation. 
These deleterious effects of smoking on skeletal muscle 
function may be mediated directly by nicotine or by other 
toxic byproducts of cigarette smoke, or indirectly as a result 
of changes in lifestyle and physical activity.
Local factors
Skeletal muscle dysfunction in COPD patients has also been 
attributed to local factors within skeletal muscle ﬁ  bers that 
may elicit speciﬁ  c changes in protein expression and func-
tion, eventually resulting in reduction of muscle mass and 
depressed contractile functions. These factors include oxida-
tive and nitrosative stress of muscle ﬁ  bers and changes in the 
balance between protein synthesis and degradation.
Oxidative and nitrosative stress
Both ROS and RNS species are highly reactive molecules 
normally produced at relatively low levels inside skeletal 
muscle ﬁ  bers. ROS are derived from superoxide anion (O2
•-) 
while RNS are derived from nitric oxide (NO•). In normal 
skeletal muscle fibers, ROS are produced at relatively 
low levels and play a positive role in maintaining muscle 
contractility (Reid 1996). However, increased production 
of these species, to levels signiﬁ  cantly greater than those 
that can be neutralized by intracellular antioxidant defenses, 
leads to the development of a state of oxidative stress, 
which has profound effects on action potential conduction, 
excitation–contraction coupling, contractile proteins, and 
mitochondrial respiration (Reid 1996).
NO• is formed from L-arginine by nitric oxide synthases 
(NOSs). Three distinct NOS isoforms have been identi-
ﬁ  ed: neuronal (nNOS) and endothelial (eNOS), which are 
constitutively expressed in many cell types; and inducible 
NOS (iNOS), which is induced by pro-inﬂ  ammatory cyto-
kines (El-Dwairi et al 1998; Stamler and Meissner 2001). 
In normal mammalian skeletal muscles, a special form of 
nNOS (nNOSμ) is expressed close to the sarcolemma and 
musculo-tendon junction (Kobzik et al 1994; Brenman 
et al 1995) whereas the eNOS isoform is expressed inside 
the mitochondria of mature muscles (Kobzik et al 1995). International Journal of COPD 2008:3(4) 647
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iNOS is induced inside the cytosol of skeletal muscles in 
septic humans and other animals and in cultured myoblasts 
exposed to inﬂ  ammatory cytokines. Constitutive NO produc-
tion inside skeletal muscle ﬁ  bers modulates glucose transport 
and insulin-mediated skeletal muscle vasodilation (Steinberg 
et al 1994; Baron 1996; Balon and Nadler 1997; Kapur et al 
1998; Roberts et al 1998). In addition, NO promotes vaso-
dilation of skeletal muscle vasculature by acting directly on 
smooth muscles (Hussain et al 1992), whereas NO synthe-
sized within the muscles, nNOS, promotes vasodilation of 
muscle vessels by inhibiting sympathetic vasoconstriction 
(Thomas et al 1998; Thomas and Victor 1998).
In contrast to the regulatory roles that physiological 
levels of ROS and RNS play inside skeletal muscle ﬁ  bers, 
excessive levels of ROS and RNS provoke a diverse array 
of deleterious effects that are attributed to peroxidation of 
membrane phospholipids, carbonyl formation and nitration 
of tyrosine residues. Peroxidation of membrane lipids leads 
to the fragmentation of polyunsaturated fatty acids, resulting 
in the production of various cytotoxic and highly reactive 
aldehydes, alkenals, and hydroxyalkenals such as malonal-
dehyde (MDA) and 4-hydroxy-2-nonenal (HNE) (Halliwell 
and Gutteridge 1989). In comparison, carbonyls are formed 
as a result of oxidation of the amino acids arginine, lysine, 
threonine, and proline (Davies 2003). As yet, the inﬂ  uence of 
tyrosine nitration on muscles has not been fully uncovered, 
although it is known to adversely affect protein function and 
is linked to severity status of COPD in both acute and chronic 
situations (Montes de Oca et al 2005).
The development of oxidative and nitrosative stress has 
been documented in the plasma, urine and skeletal muscles 
of COPD patients, both at rest and following exercise. In 
patients with severe COPD, urinary MDA levels, and H2O2 
concentrations in breath condensate are signiﬁ  cantly higher 
than those measured in control subjects (Mercken et al 2005). 
In resting quadriceps muscles of patients with severe COPD, 
total glutathione concentrations are lower whereas the levels 
of HNE and lipofuscin (products of lipid peroxidation) are 
signiﬁ  cantly higher than those detected in control subjects 
(Engelen et al 2000a; Allaire et al 2002; Barreiro et al 2003). 
In addition, resting limb muscles of COPD patients have 
increased protein tyrosine nitration and elevated levels of 
iNOS protein, suggesting the development of nitrosative 
stress (Barreiro et al 2003; Montes de Oca et al 2005). With 
respect to exercise, patients with moderate to severe COPD 
have elevated ROS-induced DNA damage in peripheral 
blood mononuclear cells, plasma uric acid, blood oxidized 
glutathione and lipid peroxides levels at the end of whole 
body exercise indicating that these patients experience 
systemic oxidative stress, even during normal daily activity 
(Vina et al 1996; Heunks et al 1999; Mercken et al 2005). 
Couillard and colleagues (2002) have proposed that exer-
cising limb muscles might be an important source of ROS 
products released into the plasma of COPD patients. This is 
supported by observations that carbonyl formation and lipid 
peroxidation increase signiﬁ  cantly in quadriceps muscles of 
patients with severe COPD (Couillard et al 2003).
In contrast to the amount of research using the quadriceps 
muscle, little information is yet available regarding altera-
tions in the redox status of the diaphragm in COPD patients. 
Barriero and colleagues (2005a) were the ﬁ  rst to report 
that carbonyl and HNE-protein adducts were signiﬁ  cantly 
elevated in the diaphragms of patients with severe COPD 
(Figure 4). At the same time, these authors found no rise 
in protein tyrosine nitration in the diaphragms of patients 
with severe COPD. A more recent study by Wijnhoven and 
colleagues (2006) failed to detect a rise in lipid peroxida-
tion in the diaphragms of patients with moderate and severe 
COPD patients. These contradictory results are likely due to 
the relatively low number of diaphragm samples that were 
examined and to differences in the methodologies that were 
used to evaluate oxidant and antioxidant levels. So, despite 
clear evidence of the development of oxidative stress in limb 
muscles of COPD patients, the contribution of oxidative 
stress to the contractile dysfunction of these muscles remains 
under investigation, although indirect evidence supports a 
strong role for oxidative stress in depressed skeletal muscle 
strength and endurance.
Targets of ROS and RNS in skeletal muscles
ROS and RNS inﬂ  uence skeletal muscle contractile perfor-
mance by targeting several enzymes involved in mitochon-
drial respiration, glycolysis and Ca++ ﬂ  ux. It has long been 
recognized that complex I, II, and IV of the mitochondrial 
respiratory chain are particularly sensitive to the inhibitory 
effects of ROS and RNS (Cleeter et al 1994; Murray et al 
2003). Other targets in the mitochondria include Krebs cycle 
oxidative enzymes such as aconitase, which is inhibited 
and degraded when exposed to H2O2 and O2
•- (Bulteau et al 
2003). Creatine kinase (CK) is another target of ROS and 
RNS inside quadriceps muscles of COPD patients (Barreiro 
et al 2005c). Others have conﬁ  rmed that CK is sensitive to 
ROS generation during skeletal muscle ﬁ  ber injury (Pierce 
et al 2007) and is also target of peroxynitrite and lipid per-
oxidation products (Kanski et al 2005; Eliuk et al 2007). In 
quadriceps muscles of COPD patients, the activity of CK International Journal of COPD 2008:3(4) 648
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is inversely related to the intensity of carbonylation of this 
protein, suggesting that CK activity is inhibited in these 
muscles (Barreiro et al 2005c).
Enzymes involved in glycolysis are also targeted by both 
ROS and RNS inside skeletal muscles. These enzymes include 
enolase, aldolase and glyceraldehyde 3-phosphate dehydro-
genase, which are strongly carbonylated, HNE-modiﬁ  ed and 
tyrosine nitrated within the diaphragm (Barreiro et al 2005b; 
Hussain et al 2006; Vassilakopoulos et al 2007). These 
modiﬁ  cations are likely to inhibit their activities (Souza 
and Radi 1998; Barreiro et al 2005b; Hussain et al 2006; 
Vassilakopoulos et al 2007). However, whether or not the 
inhibitory effects of ROS and RNS on glycolytic enzymes 
are sufﬁ  cient to alter glucose metabolism of skeletal muscle 
ﬁ  bers remains to be investigated. Other proteins modiﬁ  ed by 
ROS and RNS inside skeletal muscles include Na+/K+ pump 
(Kurella et al 1995), Ca++ ATPase (Viner et al 1997; Klebl et al 
1999) and ryanodine receptor channels (RyR) (Sun et al 2001). 
Finally, ROS and RNS might also target several myoﬁ  brillar 
proteins including actin, myosin heavy chain and light chain, 
tropomyosin, γ-actin and actinin (Milzani et al 2000; Kim et al 
2002; Kanski et al 2005; Vassilakopoulos et al 2007). Modiﬁ  -
cations of these proteins by ROS and RNS lead to alterations 
in function, changes in Ca++ and increased degradation.
Molecular sources of ROS and RNS
Although detailed mechanisms behind the development 
of oxidative stress in skeletal muscles of COPD patients 
remain under investigation, conventionally the process has 
been attributed to an imbalance between the rate of oxidant 
production and the levels of antioxidant defenses.
Mitochondria
The mitochondria are major sites of intracellular ROS pro-
duction as 5% of molecular O2 is reduced to O2
-• as a result 
of electron leaks from the respiratory chain. Two ﬁ  ndings 
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Figure 4 A) Representative examples of protein oxidation (total carbonyl groups) in diaphragms of control subjects and patients with moderate and severe COPD. B) Mean 
values ± SD of total carbonyl formation higher in the patients with severe COPD, compared to control subject muscles (*p = 0.05).   No difference in total diaphragmatic 
carbonyl formation between patients with moderate COPD and control subjects (ns = nonsigniﬁ  cant).   Among overall patients with COPD, optical densities of total carbonyl 
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with moderate COPD have FEV1 and FVC of 62 ± 4 and 72% ± 11% of predicted, respectively. Patients with severe COPD have FEV1 and FVC of 42 ± 7 and 54% ± 9% of 
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suggest that mitochondrial membrane potentials might be 
abnormally elevated in limb muscles of COPD patients and 
might trigger an increase in ROS production. Sauleda and 
colleagues (1998) have reported that cytochrome c oxidase 
activity (complex IV) is signiﬁ  cantly increased in quadriceps 
muscles of COPD patients with respiratory failure. However, 
because the expression of 12S ribosomal RNA (biomarker of 
mitochondrial biogenesis) is also increased in these patients, 
it is unclear as to whether the observed rise in cytochrome 
c oxidase activity is due to increased mitochondrial number 
or genuine augmentation of cytochrome c oxidase activity 
in a given mitochondrion, or both. Additionally, Gosker and 
colleagues (2003b) and Russell and colleagues (2004) have 
shown that the expression of uncoupling protein 3 (UCP3, 
uncouples oxidative phosphorylation from mitochondrial 
membrane potentials) is signiﬁ  cantly reduced in quadriceps 
muscles of COPD patients. Although attenuation of UCP3 
is likely to trigger augmentation of mitochondrial ROS 
production, direct measurements of this production in limb 
and ventilatory muscles of COPD are clearly required to 
elucidate the contribution of mitochondrial sources to overall 
ROS production.
Xanthine oxidase
Under physiological conditions, hypoxanthine and xanthine 
are oxidized to uric acid by xanthine dehydrogenase, 
however, under hypoxic or ischemic conditions, xanthine 
dehydrogenase is converted to xanthine oxidase, which pref-
erentially reduces molecular O2 to O2
-• and H2O2 (Engerson 
et al 1987). During exercise, both hypoxia and increased 
levels of xanthine and hypoxanthine inside skeletal muscle 
ﬁ  bers cause signiﬁ  cant elevation of xanthine oxidase activity. 
As in the case of mitochondrial ROS production, little direct 
evidence of increased xanthine oxidase in skeletal muscles 
of COPD has been published thus far, although Heunks and 
colleagues (1999) have reported that pre-treatment with the 
xanthine oxidase inhibitor allopurinol signiﬁ  cantly attenuates 
exercise-induced elevation of plasma oxidized glutathione 
and MDA levels in patients with COPD who have performed 
incremental exercise. Whether or not allopurinol treatment 
attenuates oxidative stress inside muscle ﬁ  bers of exercising 
muscles remains unclear.
NADPH oxidase
NADPH oxidase is an enzyme complex ﬁ  rst described in 
phagocytes, where it consists of four essential subunits 
(p22phox, gp91phox (Nox2), p47phox and p67phox) and two 
additional subunits (p40phox and Rac2). NADPH oxidase is 
also expressed in nonphagocytes where it produces ROS 
under basal conditions but, upon stimulation, ROS are pro-
duced intracellularly at much lower levels than they are in 
phagocytes. Recent studies have conﬁ  rmed the presence of 
Nox2, p47phox, p67phox and p22phox subunits in skeletal muscle 
samples and have implicated these subunits in the regula-
tion of Ca++ inﬂ  ux and insulin signaling (Hidalgo et al 2006; 
Javeshghani et al 2002; Espinosa et al 2006; Wei et al 2006). 
These studies clearly suggest that NADPH oxidase-derived 
ROS play important physiological roles in regulating skeletal 
muscle signaling. On the basis of these results, one would 
not expect that a mild to moderate augmentation of muscle-
derived NAPDH oxidase activity would contribute to the 
development of oxidative stress in skeletal muscles of COPD 
patients. In comparison, neutrophil- and macrophage-derived 
NADPH oxidases are more likely to generate pathological 
levels of ROS that elicit oxidative stresses in skeletal muscles. 
However, there is little evidence that signiﬁ  cant neutrophil 
and macrophage inﬁ  ltration develops in skeletal muscles of 
COPD patients. In fact, normal numbers of inﬂ  ammatory 
cells have been detected in the vastus lateralis muscles of 
patients with COPD (Gosker et al 2003a).
Nitric oxide synthases
Muscle redox state is strongly inﬂ  uenced by NO produc-
tion, since increased NO levels in the presence of enhanced 
O2
−• levels leads to the production of the highly reactive 
peroxynitrite. Few studies have as yet explored whether or 
not NO production and NOS expression are altered in skeletal 
muscles of COPD patients. Several studies have reported 
that the levels of nNOS and eNOS proteins in quadriceps of 
patients with severe and moderate COPD are similar or even 
lower than that those of control subjects (Barreiro et al 2003, 
2008a; Montes de Oca et al 2005). In comparison, others 
described induction of the iNOS isoform in quadriceps of 
patients with severe COPD patients, particularly those with 
low BMI (Agusti et al 2004; Montes de Oca et al 2005; 
Barreiro et al 2008a). In addition, elevated protein tyrosine 
nitration in quadriceps muscles of COPD patients has been 
documented by many authors thereby conﬁ  rming an increase 
in peroxynitrite formation in these patients (Barreiro et al 
2003; Agusti et al 2004; Montes de Oca et al 2005). It is 
worth noting that not all skeletal muscles of COPD patients 
show evidence of nitrosative stress and peroxynitrite forma-
tion. For instance, Barreiro and colleagues (2005a) found no 
signiﬁ  cant differences in protein tyrosine nitration, despite the 
presence of elevated protein carbonylation and 4HNE-protein 
adduction formation, in the diaphragms of patients with International Journal of COPD 2008:3(4) 650
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moderate and severe COPD. In fact, the production of NO 
in the diaphragms of these patients might have been even 
lower than in normal subjects, as indicated by the presence 
of lower eNOS protein levels (Barreiro et al 2005a). Thus, 
while oxidative stress develops in the diaphragms of patients 
with COPD, there is little evidence that nitrosative stress also 
develops in that muscle.
The development of oxidative stress in skeletal muscles of 
COPD patients has also been attributed to reduction in anti-
oxidant capacity. Early reports suggest that plasma levels of 
nonenzymatic antioxidants are signiﬁ  cantly lower in COPD 
patients, both at rest and after localized exercise, than they are 
in control subjects (Rahman et al 1996; Couillard et al 2002). 
Measurements of protein levels and activities of antioxidant 
enzymes reveal that in patients with severe COPD patients 
and signiﬁ  cant muscle wasting, Mn-SOD and glutathione-
S-transferase activities in resting quadriceps muscles are 
signiﬁ  cantly elevated (Gosker et al 2005; Barreiro et al 
2008a). However, the levels of Mn-SOD, catalase, heme 
oxygenase-1 and glutathione peroxidase (an important 
enzyme in the metabolism of glutathione) in the quadriceps 
muscles and diaphragms of patients with moderate COPD 
are not different from control subjects (Couillard et al 2003; 
Barreiro et al 2003, 2005a, 2008a).
Despite similarities in antioxidant enzyme levels, the 
response of these enzymes to increased oxidant produc-
tion elicited by exercise or exercise training appears to be 
abnormal. Indeed, Couillard and colleagues (2003) have 
reported that glutathione peroxide activity in quadriceps 
muscles of patients with moderate COPD remains unchanged 
from resting values following localized quadriceps muscle 
endurance exercise, while the activity of the same enzyme 
rises signiﬁ  cantly in control subjects. A similar lack of 
augmentation of Mn-SOD activity in response to endurance 
training of quadriceps muscles has been observed in patients 
with moderate COPD (Barreiro et al 2008a). These results 
suggest that exercise-induced oxidative stress does indeed 
develop in limb muscles of COPD patients, in part as a result 
of an inability of antioxidant enzymes to respond to increased 
oxidant production.
Regulation of protein synthesis/
degradation
Regulation of muscle mass is a dynamic process involving 
a delicate balance between hypertrophic (protein synthesis) 
and atrophic (degradation) signalling pathways. There are 
four classes of proteolytic enzymes that are involved in 
protein degradation inside skeletal muscles. In different 
models of muscle wasting there is coordinated stimulation 
of these systems, which include the proteasomal and the 
lysosomal pathways, calpains and caspases. Proteins tar-
geted for degradation go through several steps, the ﬁ  rst of 
which involves the activation of ubiquitin by E1 ubiquitin-
activating proteins and then a transfer of activated ubiquitin 
to E2 ubiquitin conjugating enzymes and, ﬁ  nally, eventual 
transfer of ubiquitin to the targeted proteins. Two muscle-
speciﬁ  c E3 ligases, namely, muscle ring ﬁ  nger (MuRF1) and 
muscle atrophy F-box (MAFbx or atrogin-1) have recently 
been cloned and have been shown to be signiﬁ  cantly induced 
inside muscle ﬁ  bers in various models of muscle atrophy, 
including denervation, immobilization and fasting (Bodine 
et al 2001). Upstream signals that mediate the activation of 
the ubiquitin–proteasome pathway in skeletal muscle atrophy 
remain unclear. However, recent studies have indicated that 
expressions of atrogin-1 and MuRF1 are controlled by a 
complex signaling network comprised of the FoxO transcrip-
tion factors (Sandri et al 2004) and their upstream regulators, 
including protein kinase B (AKT) (Cai et al 2004).
The second step involves the lysosomal system, which 
consists of several cathepsins (acid hydrolases), glycosidases, 
lipases, nucleases and phosphatases, and is responsible for 
degradation, through autophagy, of most membrane and 
extracellular proteins taken up by endocytosis, in addition 
to cytoplasmic proteins and organelles (Scott and Klionsky 
1998). Calpains consist of fourteen different cysteine pro-
teases that are dependent on Ca++. Skeletal muscles contain 
substantial levels of two ubiquitous calpains, one that 
requires micromolar concentrations of Ca++ (μ-calpain), 
and one that requires millimolar levels of Ca++ (m-calpain), 
in addition to the calpain inhibitor calpstatin (Bartoli and 
Richard 2005). Calpains cleave proteins at selective sites 
and are not involved in the degradation of cytosolic proteins 
inside skeletal muscles. Finally, caspases are responsible 
for degrading cellular proteins during apoptosis and many 
recent reports have documented increases in caspase activ-
ity and/or expression inside skeletal muscles in a variety of 
pathological conditions, including muscular dystrophy, sepsis 
and exercise-induced oxidative stress (Supinski and Callahan 
2006; Huey et al 2008; Kocturk et al 2008). Although it is 
known that caspase-3 acts upstream from the proteasomal 
pathway and that it is capable of degrading actin in in vitro 
settings (Du et al 2004), the exact contributions of caspases to 
in vivo skeletal muscle protein degradation remain unclear.
It is generally assumed that peripheral muscle atrophy 
in patients with COPD is due to an imbalance between 
protein synthesis and degradation, in favor of the latter International Journal of COPD 2008:3(4) 651
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(Debigare et al 2001). However, the precise contributions 
of each step of the proteolysis pathway to peripheral muscle 
atrophy in COPD patients remains unclear. Debigare and col-
leagues (2003b) have shown that limb muscle atrophy in COPD 
patients may be due to an increase in the ratio of catabolic 
factors (IL6 and cortisol) to anabolic factors (testosterone, 
dehydroepiandrosterone and insulin-like growth factor-1 
[IGF-I]). Increased IL6, ROS and RNS levels are expected 
to upregulate the ubiquitin-proteasome components, while 
increased anabolic factors are expected to downregulate these 
components. In a very recent study, Debigare and colleagues 
(2008) employed microarray technology to compare gene 
expression proﬁ  les in quadriceps muscles of four patients 
with moderate or severe COPD to those of control subjects. 
They reported signiﬁ  cant upregulation of FoxO1 and FoxO3 
transcription factors in quadriceps muscles of COPD patients. 
Both transcription factors promote muscle atrophy through 
inhibition of IGF-I-mediated muscle growth and by upregu-
lating the expression of atrogin-1 and MuRF-1 (Sandri et al 
2004; Stitt et al 2004). In another study, Doucet and colleagues 
(2007) conﬁ  rmed that FoxO1 mRNA and protein and atrogin-1 
and MuRF-1 mRNA expressions are signiﬁ  cantly upregulated 
in quadriceps muscles of COPD patients, suggesting that 
the activity of the proteasomal pathway is enhanced in limb 
muscles of these patients (Figure 5). This observation cannot be 
explained by removal of the inhibitory effect of protein kinase 
B (AKT) on FoxO1 activity since AKT activity is signiﬁ  cantly 
greater in quadriceps muscles of COPD patients than it is in 
control subjects (Doucet et al 2007). It is possible that observed 
upregulations of FoxO1, atrogin-1 and MuRF-1 levels are due 
to increased activity of NFκB transcription, which is known to 
positively modulate the proteasomal pathway inside skeletal 
muscle (Cai et al 2004).
Activation of the ubiquitin-proteasomal pathway is not 
limited to the limb muscles of COPD patients. Activity of 
the 20S proteasome and atrogin-1 expression have recently 
been shown to be upregulated by 3-fold in the diaphragms 
of patients with mild to moderate COPD (Ottenheijm et al 
2006b). While these studies imply that the proteasomal path-
way contributes to proteolysis of skeletal muscle proteins in 
COPD patients, no information is as yet available about the 
relative contributions of the lysosomal, calpain and caspase 
pathways to the atrophy process. Systematic and thorough 
investigations of how, where, and when these pathways are 
activated, and thus contribute to muscle protein degradation, 
are clearly needed in relation to patients with COPD.
To further explore the functional importance of FoxO 
transcription factors in regulating muscle protein degradation 
in COPD patients, for the present study the dataset of 
Debigare and colleagues (2008) was analyzed using Inge-
nuity Pathway Analysis software (http://www.ingenuity.
com/) to show that three major networks link the majority 
of signiﬁ  cantly regulated genes in the quadriceps muscles of 
COPD patients. Figure 6 shows the top network uncovered 
by this analysis. This network contains several highly con-
nected nodes, such as FoxO1 and FoxO3, as well as NFκB 
transcription factors and two signaling pathways related 
to mitogen activated protein kinases, namely, the Erk1/2 
and p38 pathways. Network analysis suggests that elevated 
expression and/or activation of FoxO1, FoxO3 and NFκB 
transcription factors in quadriceps muscles of COPD patients 
might be due to both abnormalities in the insulin pathway 
and attenuation of FHL2 expression.
FHL2 (four-and-a-half LIM only protein 2) is a member 
of a family of proteins containing the LIM domain, a con-
served cysteine-rich module that plays several important 
roles as an adaptor or as a scaffold to support the assembly 
of multimeric protein complexes (Johannessen et al 2006). In 
skeletal muscles, FHL2 promotes differentiation of myoblasts 
into myotubes (Martin et al 2002) and functions as an adaptor 
molecule that links the metabolic enzymes creatine kinase, 
adenylate cyclase and phosphofructokinase to titin, a protein 
that plays a crucial role as organizer of the sarcomere (Lange 
et al 2002). In addition, FHL2 directly interacts with FoxO1 
and suppresses its transcriptional activity (Yang et al 2005). 
Furthermore, deletion of FHL2 augments TRAF6-dependent 
NFκB activity, suggesting that a role of FHL2 is to attenuate 
NFκB activity (Bai et al 2005). The fact that FHL2 expres-
sion is signiﬁ  cantly downregulated in quadriceps muscles of 
COPD patients raises the possibility that the increased activi-
ties of FoxO1, FoxO3 and NFκB transcription factors might 
be due to attenuation of the inhibitory effects of FHL2 on 
the activity and/or expression of these factors (Debigare et al 
2008). This network analysis also suggests that FoxO1 and 
FoxO3 transcription factors may be involved in regulating 
the expression of UCP2 and troponin C in muscles in these 
patients (Figure 6). Clearly, additional studies are required 
to fully elucidate the functional roles, not only of FoxO and 
NFκB transcription factors, but also of all factors related to 
the FHL2 and insulin pathways in mediating skeletal muscle 
dysfunction.
Vascular density and capillarization
Little information is available about changes in capillary 
density in skeletal muscles of COPD patients. An initial 
study by Jobin and colleagues conﬁ  rmed that capillary to International Journal of COPD 2008:3(4) 652
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muscle ﬁ  ber ratios in the vastus lateralis muscle of patients 
with severe COPD are about 47% lower than those mea-
sured in the same muscle of age-matched control subjects 
(Jobin et al 1998). A subsequent study by the same group 
reported relatively smaller reductions in the capillary to 
ﬁ  ber ratio in the muscles of patients with mild to moder-
ate COPD (Whittom et al 1998). Reduction in capillary 
density is thought to have a deleterious effect on muscle 
oxidative capacity. This is indeed the case in limb muscles 
of COPD patients, where the activities of citrate synthase 
and 3-hydroxyacyl coenzyme A dehydrogenase (markers 
of oxidative capacity) are signiﬁ  cantly reduced (Maltais 
et al 2000). The decline in the activity of citrate synthase 
is proportional to the deterioration of functional status of 
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Figure 5 A) Atrogin-1 mRNA expression; B) MuRF1 mRNA expression; C) representative Western blot for atrogin-1; D) atrogin-1 protein expression, all from quadriceps 
muscles of control subjects and COPD patients. Expression data relative to control values and presented in AU. mRNA data normalized for RPLPO, cytoplasmic protein con-
tents normalized for α-tubulin. E) Signiﬁ  cant correlation between atrogin-1 and MuRF1 mRNA expressions (r2 = 0.84; p  0.001) in COPD patients. Values are mean ± SEM; 
*p  0.05; +p  0.001. Copyright © 2007.   Adapted from Doucet M, Russell AP, Leger B, et al 2007. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med, 176:261–9.
Abbreviations: AU, atomic units; COPD, chronic obstructive pulmonary disease; MuRF1, muscle-speciﬁ  c RING ﬁ  nger protein 1; mRNA, messenger ribonucleic acid; RPLPO, 
large ribosomal protein; SEM, standard error of mean.International Journal of COPD 2008:3(4) 653
Muscle dysfunction in COPD patients
the muscle (Maltais et al 2000). However, because total 
muscle mitochondrial density is signiﬁ  cantly reduced in 
COPD patients (Gosker et al 2007a), it is unclear whether 
or not the observed reduction in oxidative enzyme capacity 
is due to attenuation of total mitochondrial number and/or 
to speciﬁ  c defects in the activity of these enzymes. It 
should be emphasized that reduction in skeletal muscle 
mitochondrial density in COPD patients is muscle-speciﬁ  c; 
it has been described in the vastus lateralis muscle but not 
in the tibialis muscle (Gosker et al 2007a). Attenuation of 
capillary and mitochondrial densities in skeletal muscles of 
COPD patients is associated with augmentation of serum 
and muscle lactic acid levels during exercise and an early 
onset of contractile fatigue (Maltais et al 1996; Engelen 
et al 2000b).
The precise mechanisms behind reduction in capillary 
density in limb muscles of COPD patients are not clear. 
Very recently, Barreiro and colleagues (2008b) have reported 
that vascular endothelial growth factors (VEGF) protein 
levels in the vastus lateralis of patients with moderate and 
severe COPD are signiﬁ  cantly lower than those of control 
subjects. These observed reductions in VEGF levels cannot 
be explained by inactivity or ﬁ  ber type switching since no 
relationship was found between VEGF muscle levels and 
exercise tolerance parameters or ﬁ  ber type distribution (Bar-
reiro et al 2008b). Expression of VEGF in the vastus lateralis 
muscles of COPD patients contrasts with that expressed in the 
diaphragm, which shows mildly, but signiﬁ  cantly, elevated 
VEGF levels in patients with moderate COPD (Alexopoulou 
et al 2005). It should be noted that upregulation of VEGF 
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expression in the diaphragms of COPD patients, which is not 
paralleled by an increase in ﬁ  broblast growth factor-1 and 
TGFβ expressions, cannot be attributed to increased mechani-
cal loads in these patients, although other local factors such as 
ﬁ  ber type remodeling and hypoxemia may be involved. The 
involvement of pro- and anti-angiogenesis factors other than 
VEGF in the regulation of skeletal muscle capillary density 
in COPD patients remains to be explored.
Summary
In this review, we have collected evidence indicating that 
both strength and endurance of skeletal muscles in general, 
and limb muscles in particular, are reduced in patients with 
COPD and that these abnormalities are associated with 
attenuated exercise capacity and increased mortality. Exami-
nations of muscle biopsies in COPD patients reveals that 
lower limb muscles in particular undergo speciﬁ  c structural 
and functional alterations that are similar, but not identi-
cal, to those found in muscles that are atrophied as a result 
of denervation or disuse. More recent studies support the 
notion that, in addition to disuse/de-conditioning-induced 
atrophy, skeletal muscle dysfunctions in COPD patients 
might be due to myopathy triggered by systemic factors, 
including inﬂ  ammation, nutritional depletion, corticosteroid 
use, chronic inactivity, age, hypoxemia, and smoking, and 
local factors due to selective increases in reactive oxygen 
and nitrogen species production, enhanced proteolysis, and 
changes in vascularization. Further studies are required to 
identify the precise molecular mechanisms responsible for 
skeletal muscle dysfunction in COPD patients.
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